FindTrial
Sign In

Serum Antimullerian hormone - a potential marker in blood for identifying women with multiple cystic conditions in the ovary among the regional population

Serum AMH level- a potential biomarker for diagnosing women with PCOS among regional population - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/08/093734
Enrollment
137
Registered
2025-08-27
Start date
Unknown
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E282- Polycystic ovarian syndrome

Interventions

Intervention1: Nil: Nil

Sponsors

Dr Sandhya Babu
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Women fulfilling Rotterdam?s criteria at or above 20 years of age

Exclusion criteria

Exclusion criteria: - Women who underwent any gynaecological procedure (ovarian drilling, cystectomy, etc.) - Women who are already on management for PCOS, like ovarian drilling, infertility treatment, etc. - Women with other gynaecological complaints like adenomyosis, fibroid or severe endometriosis.

Design outcomes

Primary

MeasureTime frame
Serum AMH level- a diagnostic tool in diagnosing PCOSTimepoint: 12 MONTHS—

Secondary

MeasureTime frame
To compare Serum AMH levels with or without hirsutism To compare Serum AMH levels with normal and abnormal sonological findings To predict Serum testosterone level among PCOS Timepoint: 12 MONTHS—

Countries

India

Contacts

Public ContactGrace ManoR

Sandhya Hospital

drgracemohan7@gmail.com9865199715

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026